Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 548as (miR-548as, hsa-mir-548as, MIR548AS) is a member of the large, **primate-specific miR-548 microRNA gene family**[2][4]. MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression post-transcriptionally by binding to complementary sequences in target messenger RNAs (mRNAs), resulting in translational repression or mRNA degradation[3]. The miR-548 family influences numerous biological pathways, including proliferation, apoptosis, immune signaling, and cancer-related pathways[1][2][4]. miR-548ah (a closely related family member) has been shown to target key immune receptors, such as IFN-γR1, suppressing immune responses and playing a role in viral pathogenesis and immune regulation in chronic hepatitis B[1]. Various members of the miR-548 family, including miR-548a-5p, have been implicated in the regulation of **tumor suppressor genes (e.g., Tg737)** and have functional roles in hepatocellular carcinoma and other cancers by modulating cell cycle, proliferation, and apoptosis[2]. Expression levels of miR-548 family members have shown utility as biomarkers for disease states, particularly in cancer and cardiovascular disease[2][3]. There is currently no evidence that miR-548as itself is a *direct therapeutic target* (such as a receptor, enzyme, transporter, or ion channel), and it is more accurately described as a *regulatory RNA molecule* or a disease biomarker[2][3][4]. **Important note:** There is insufficient public characterization of the specific miR-548as (MIR548AS, hsa-mir-548as) variant in peer-reviewed sources; most detailed studies refer to related members of the miR-548 family (miR-548ah, miR-548a-5p, miR-548d-3p, etc.), some of which are sometimes inconsistently labeled. The core features described above reflect the overall biology and known functions of the miR-548 family[2][4]. If you require information about a specifically validated therapeutic target, miR-548as would not be classified as such at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 548as (miR-548as).